Literature DB >> 8530809

Structure and expression of the cyclin A gene in human primary liver cancer. Correlation with flow cytometric parameters.

P Paterlini1, J F Flejou, M S De Mitri, E Pisi, D Franco, C Bréchot.   

Abstract

BACKGROUND/AIMS: The cyclin A gene plays an important role in both the S and G2-M phases of the cell cycle, and has been identified at a site of hepatitis B virus DNA integration in a human liver cancer. We analyzed tumorous and non-tumorous samples from patients with primary liver cancer to determine whether a) the cyclin A gene is rearranged in liver tumors and b) the cyclin A transcript level correlates with the percentage of proliferating cells.
METHODS: Samples from 43 patients were analyzed by Southern blot. Cyclin A RNA accumulation was evaluated in 18 cases by slot blot and correlated with the percentage of cells in S plus G2-M phases defined by flow cytometry.
RESULTS: No rearrangement of the cyclin A gene was found in tumorous compared to non-tumorous tissue. A very strong positive correlation was found between the cyclin A RNA level and the cumulative percentage of cells in S plus G2-M phases (r = 0.99; p < 0.0001).
CONCLUSIONS: This in vivo study shows that the expression of cyclin A RNA correlates with the percentage of proliferating cells in primary liver cancer. Thus, cyclin A is a new potential liver tumor cell proliferation index.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8530809     DOI: 10.1016/0168-8278(95)80310-6

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  11 in total

1.  Influence of PDGF-BB on proliferation and transition through the MyoD-myogenin-MEF2A expression program during myogenesis in mouse C2 myoblasts.

Authors:  Z Yablonka-Reuveni; A J Rivera
Journal:  Growth Factors       Date:  1997       Impact factor: 2.511

2.  Association between nm23-H1 expression, proliferation and apoptosis in non-small cell lung carcinomas.

Authors:  M Volm; J Mattern; R Koomägi
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

3.  Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions.

Authors:  J Georgieva; P Sinha; D Schadendorf
Journal:  J Clin Pathol       Date:  2001-03       Impact factor: 3.411

4.  Novel F141L pre-S2 mutation in hepatitis B virus increases the risk of hepatocellular carcinoma in patients with chronic genotype C infections.

Authors:  Ho-Suk Mun; Seoung-Ae Lee; Hong Kim; Eung-Soo Hwang; Yoon-Hoh Kook; Bum-Joon Kim
Journal:  J Virol       Date:  2010-10-20       Impact factor: 5.103

5.  Activation of anchorage-independent growth of HT1080 human fibrosarcoma cells by dexamethasone.

Authors:  Nobuo Kondoh; Masahiro Shuda; Masaaki Arai; Tsuneyuki Oikawa; Mikio Yamamoto
Journal:  In Vitro Cell Dev Biol Anim       Date:  2002-02       Impact factor: 2.416

6.  Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas.

Authors:  M Volm; W Rittgen; P Drings
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

7.  Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas.

Authors:  M Volm; R Koomägi; J Mattern; G Stammler
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival.

Authors:  M Volm; R Koomägi
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

9.  The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations.

Authors:  Xavier Bisteau; Matias J Caldez; Philipp Kaldis
Journal:  Cancers (Basel)       Date:  2014-01-13       Impact factor: 6.639

10.  Male-specific hepatitis B virus large surface protein variant W4P potentiates tumorigenicity and induces gender disparity.

Authors:  Seoung-Ae Lee; Hong Kim; You-Sub Won; Seung-Hyeok Seok; YiRang Na; Han-Bo Shin; Kyung-Soo Inn; Bum-Joon Kim
Journal:  Mol Cancer       Date:  2015-02-03       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.